Description
- Mounjaro contains the active ingredient Tirzepatide
- It is a revolutionary weight-loss injection that offers a clinically proven approach to managing obesity.
- It was developed by the pharmaceutical company Eli Lilly.
- It is a once-weekly injectable treatment designed to regulate appetite and metabolism, providing a targeted solution for sustainable weight loss.
- Mounjaro is indicated for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition.
- Mounjaro is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a first in a new class of treatments for weight loss and works by suppressing appetite, making you feel less hungry, resulting in weight loss.
- Safe for long-term use
You Might Also Like These:
Reviews
There are no reviews yet.